{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-108854","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.327659+00:00","generated_at":"2026-05-17T12:45:17.245219+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"confidence":"high","headline":"Plus Therapeutics Q2 2025: net income $5.2M on derivative gain; CNSide assay launched in Texas","bullets":["Cash $6.9M at June 30, 2025 vs $3.6M at Dec 31, 2024; operating loss $1.5M vs $3.7M in Q2 2024.","Net income $5.2M ($0.02 diluted) vs net loss $2.9M ($0.45 loss) in Q2 2024; derivative gain of $6.5M pre-tax.","CNSide CSF assay launched in Texas in Aug 2025; TAM estimated $6B; additional states planned late 2025-2026.","REYOBIQ dose optimization trial started; FDA IND clearance for pediatric high-grade glioma and ependymoma.","Received $1.6M advance from $17.6M CPRIT grant; added industry veteran Kyle Guse to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-108854","json":"https://secwatch.observer/filing/0000950170-25-108854.json","markdown":"https://secwatch.observer/filing/0000950170-25-108854.md","text":"https://secwatch.observer/filing/0000950170-25-108854.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000095017025108854/0000950170-25-108854-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000095017025108854/pstv-20250814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T12:45:17.245219+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}